Kate Haviland is a director of Fulcrum Therapeutics Inc.
Person profile
Latest filings (excl ownership)
No filings
Latest ownership filings
4
Blueprint Medicines Corp
11 Mar 24
4
Blueprint Medicines Corp
6 Mar 24
4
Fulcrum Therapeutics, Inc.
29 Jun 23
4
Blueprint Medicines Corp
8 Mar 23
4
Blueprint Medicines Corp
3 Mar 23
4
Blueprint Medicines Corp
7 Nov 22
4
Fulcrum Therapeutics, Inc.
29 Jun 22
4
Blueprint Medicines Corp
8 Mar 22
4
Blueprint Medicines Corp
3 Mar 22
4
Blueprint Medicines Corp
15 Dec 21
Recent insider trades
Date | Company | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
7 Mar 24 | BPMC Blueprint Medicines | Common Stock | Sell | Dispose S | No | No | 90.69 | 12,464 | 1.13 mm | 153,177 |
27 Jun 23 | FULC Fulcrum Therapeutics | Stock Option Common Stock | Grant | Acquire A | No | No | 3.16 | 30,000 | 94.80 k | 30,000 |
6 Mar 23 | BPMC Blueprint Medicines | Common Stock | Sell | Dispose S | No | No | 44.65 | 212 | 9.47 k | 125,641 |
6 Mar 23 | BPMC Blueprint Medicines | Common Stock | Sell | Dispose S | No | No | 45.72 | 6,428 | 293.89 k | 125,853 |
1 Mar 23 | BPMC Blueprint Medicines | Common Stock | Grant | Acquire A | No | No | 0 | 40,000 | 0.00 | 132,281 |
1 Mar 23 | BPMC Blueprint Medicines | Stock Option Common Stock | Grant | Acquire A | No | No | 43.15 | 80,000 | 3.45 mm | 80,000 |
3 Nov 22 | BPMC Blueprint Medicines | Common Stock | Buy | Acquire P | No | No | 43.98 | 1,100 | 48.38 k | 92,281 |